Jiangsu wuzhong(SH:600200) Shang Hai Zheng Quan Bao·2025-08-28 21:55Core Viewpoint - The company is facing significant operational challenges due to a breach of contract with RegenBiotech, which has led to arbitration and the inability to sell its product AestheFill, raising concerns for investors [3]. Company Overview - The company, Jiangsu Wuzhong Pharmaceutical Development Co., Ltd., has reported a substantial increase in revenue from its aesthetic biotechnology business, achieving a revenue of 268.19 million yuan in the first half of 2025, a growth of 234.73% year-on-year [20]. - Conversely, the pharmaceutical business has seen a decline in revenue, totaling 358.10 million yuan, a decrease of 53.81% compared to the previous year [20]. Financial Data - The aesthetic biotechnology segment generated a gross profit of 220.44 million yuan, up 231.94% year-on-year [20]. - The pharmaceutical segment's gross profit was 184.66 million yuan, down 32.09% year-on-year [20]. Important Events - The company’s board of directors approved the half-year report and the special report on the use of funds raised from non-public offerings, indicating compliance with relevant regulations [5][14]. - The company has announced a delay in the timeline for certain fundraising investment projects, specifically extending the deadline for the raw material drug phase II project to July 2026 [50][55]. Regulatory Issues - The company is under investigation by the China Securities Regulatory Commission for alleged violations of information disclosure laws, which may lead to a forced delisting due to significant financial discrepancies reported from 2020 to 2023 [24][27]. - The company has acknowledged the potential for its stock to be subject to major illegal delisting risks, emphasizing the importance of compliance with regulatory requirements [23][26].